Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL952 in Late-Onset Pompe Disease
NCT07354724Phase 1Recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- May 2026
- Primary completion
- Aug 2028
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of DNL952 in Pompe disease (6 cohorts), sponsored by Denali Therapeutics Inc. Primary endpoints: Treatment-Emergent Adverse Events at 48 weeks and Infusion-Related Reactions at 48 weeks. Started May 2026; status: recruiting.
02
Drugs
DNL952
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT07354724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07354724.